Trial Profile
dPD - 1 hCD19CART cells treatment of refractory, aggressive non-hodgkin's lymphoma (NHL), a safety and efficacy clinical trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs ICTCAR 014 (Primary)
- Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Apr 2022 Results (n=117) published in the Supportive Care in Cancer.
- 06 Jun 2017 Results (n=4) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 09 May 2017 New trial record